Polansky Hanan, Javaherian Adrian, Itzkovitz Edan
1 The Center for the Biology of Chronic Disease, Valley Cottage, NY, USA.
J Evid Based Integr Med. 2018 Jan-Dec;23:2515690X18806269. doi: 10.1177/2515690X18806269.
Our previous articles showed that suppressive or preventive treatment with the herbal Gene-Eden-VIR/Novirin reduced the number and duration of genital herpes outbreaks with no adverse effects. These studies also revealed that the herbal Gene-Eden-VIR/Novirin is mostly superior to acyclovir, valacyclovir, and famciclovir drugs in genital herpes. This study tested the effect of Gene-Eden-VIR/Novirin in oral herpes (also called cold sores and fever blisters).
The framework of the study was a retrospective chart review. The study included 68 participants. The participants took 1 to 4 capsules per day over a period of 2 to 36 months. The study included 2 Food and Drug Administration-recommended controls: baseline and a no-treatment.
Gene-Eden-VIR/Novirin was effective in 89.3% of participants. The treatment reduced the mean number of outbreaks per year from 6.0 and 3.6 in the control groups to 2.0 in the treatment group ( P < .0001 and P = .07, respectively). Gene-Eden-VIR/Novirin reduced the mean duration of outbreaks from 9.8 and 5.8 days in the control groups to 3.2 days in the treatment group ( P < .0001 and P = .02, respectively). There were no reports of adverse experiences. Gene-Eden-VIR/Novirin was compared to acyclovir and valacyclovir in 6 tests. In all tests, Gene-Eden-VIR/Novirin showed higher efficacy. Gene-Eden-VIR/Novirin also showed superior safety.
This clinical study showed that suppressive or preventive treatment with the herbal Gene-Eden-VIR/Novirin reduced the number and duration of outbreaks in oral herpes without any adverse effects. The study also showed that the herbal Gene-Eden-VIR/Novirin had better clinical effects than acyclovir and valacyclovir, the leading drugs in the category. Based on these results, we recommend using the herbal Gene-Eden-VIR/Novirin as preventive treatment for oral herpes and, specifically, as an alternative to the acyclovir and valacyclovir drugs.
我们之前的文章表明，使用草药制剂Gene-Eden-VIR/Novirin进行抑制性或预防性治疗可减少生殖器疱疹发作的次数和持续时间，且无不良反应。这些研究还表明，草药制剂Gene-Eden-VIR/Novirin在治疗生殖器疱疹方面大多优于阿昔洛韦、伐昔洛韦和泛昔洛韦等药物。本研究测试了Gene-Eden-VIR/Novirin对口腔疱疹（也称为唇疱疹和发热性水疱）的疗效。
本研究采用回顾性病历审查的框架。研究纳入了68名参与者。参与者在2至36个月的时间内每天服用1至4粒胶囊。本研究纳入了2个美国食品药品监督管理局推荐的对照：基线对照和不治疗对照。
Gene-Eden-VIR/Novirin对89.3%的参与者有效。治疗使每年发作的平均次数从对照组的6.0次和3.6次降至治疗组的2.0次（P值分别<0.0001和P = 0.07）。Gene-Eden-VIR/Novirin使发作的平均持续时间从对照组的9.8天和5.8天降至治疗组的3.2天（P值分别<0.0001和P = 0.02）。没有关于不良事件的报告。在6次测试中将Gene-Eden-VIR/Novirin与阿昔洛韦和伐昔洛韦进行了比较。在所有测试中，Gene-Eden-VIR/Novirin均显示出更高的疗效。Gene-Eden-VIR/Novirin还显示出更高的安全性。
这项临床研究表明，使用草药制剂Gene-Eden-VIR/Novirin进行抑制性或预防性治疗可减少口腔疱疹发作的次数和持续时间，且无任何不良反应。该研究还表明，草药制剂Gene-Eden-VIR/Novirin比该类别中的主要药物阿昔洛韦和伐昔洛韦具有更好的临床效果。基于这些结果，我们建议使用草药制剂Gene-Eden-VIR/Novirin作为口腔疱疹的预防性治疗药物，特别是作为阿昔洛韦和伐昔洛韦药物的替代品。
